Urologic Oncology-Seminars and Original Investigations

Papers
(The median citation count of Urologic Oncology-Seminars and Original Investigations is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Editorial Board45
Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors41
Oncological and functional outcomes of female reproductive organ-sparing radical cystectomy and ileal neobladder construction38
Impact of neuraxial analgesia on outcomes following radical cystectomy: A systematic review37
Predictive value of renal tumor contour irregularity score in pathological T3a upstaging of clinical T1 renal cell carcinoma: A multi-institutional study30
Conditional survival after radical cystectomy for non-metastatic muscle-invasive squamous cell carcinoma of the urinary bladder: A population-based analysis27
Interpreting nephrometry scores with three-dimensional virtual modelling for better planning of robotic partial nephrectomy and predicting complications26
An update on the pathology of collecting duct & papillary renal cell carcinoma with a discussion of SNP-Arrays as an emerging laboratory technique26
Introduction to the seminar on “the impact of complications on surgeons”25
Bilateral inguinal lymphadenectomy using simultaneous double laparoscopies for penile cancer: A retrospective study25
Differences in cancer presentation, treatment, and mortality between rural and urban patients diagnosed with kidney cancer in the United States25
Meta-analysis of perioperative immunotherapy in renal cell carcinoma: Available, but the jury is still out25
Characteristics, trends, and management of Penile cancer in the United States: A population-based study24
Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy23
Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey23
Editorial Board23
Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients22
The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment22
Renal cell carcinoma with tumor thrombus: A review of relevant anatomy and surgical techniques for the general urologist21
Inverted urethral flap reconstruction after partial penectomy: Long-term oncological and functional outcomes21
Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis21
Letter to the Editor, Re: Reitblat et al. 202121
Age related differences in primary testicular lymphoma: A population based cohort study20
“Advancing bladder preservation: Biomarkers, decision-making, and therapy”20
Radical cystectomy and urinary diversion outcomes in patients with single vs. double renal unit: A 2:1 matched-pair analysis20
Distinguishing lipid-poor angiomyolipoma from renal carcinoma using tumor shape19
Cover 2 - Masthead19
Regional differences in upper tract urothelial carcinoma patients across the United States18
Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer18
The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy18
Acute kidney injury as an independent predicting factor for stage 3 or higher chronic kidney disease after nephrectomy18
The role of multiparametric MRI in active surveillance for low-risk prostate cancer: The ROMAS randomized controlled trial17
PIVOTAL STUDY OF MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION (TULSA) OF LOCALIZED PROSTATE CANCER: 5-YEAR FOLLOW UP17
Cover 3 - GF 39717
Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma – An exploratory analysis17
Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers17
Predictors of discharge to home following major surgery for urologic malignancies: Results from the national surgical quality improvement program17
Extraperitonealization of ileal conduit reduces parastomal hernia after cystectomy and ileal conduit diversion17
Patient empowerment through engagement in bladder cancer research17
Table of Contents16
Disparities in precision medicine—Examining germline genetic counseling and testing patterns among men with prostate cancer16
Detection of clinically significant prostate cancer by transperineal multiparametric magnetic resonance imaging-ultrasound fusion targeted prostate biopsy in smaller prostates16
Deep learning model for the detection of prostate cancer and classification of clinically significant disease using multiparametric MRI in comparison to PI-RADs score16
Table of Contents16
Characterization of perioperative androgen profiles in men with bladder cancer undergoing radical cystectomy16
The impact of routine frozen section analysis during nephroureterectomy or segmental ureterectomy for urothelial carcinoma on final surgical margin status and long-term oncologic outcome15
Comparison of aggressiveness in central versus peripheral T1a clear-cell renal cell carcinoma14
Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for seminoma: Limitations of surgical intervention after first-line chemotherapy14
Diagnostic renal mass biopsy is associated with individual categories of PADUA and RENAL nephrometry scores: Analysis of diagnostic and concordance rates with surgical resection14
Incidence and risk factors of suicide among patients diagnosed with bladder cancer: A systematic review and meta-analysis14
Exploring knowledge, perspectives, and misperceptions of palliative care: A mixed methods analysis14
Infectious complications associated with perioperative blood transfusion in partial or radical nephrectomy14
Clock gene NR1D1 might be a novel target for the treatment of bladder cancer14
Guideline discordant care in patients with metastatic germ cell tumors13
Pathologic fracture in metastatic kidney cancer: Identifying widening disparities and opportunity for quality improvement13
Radical prostatectomy for patients with high-risk, very-high risk, or radiographic suspicion for metastatic prostate cancer: Perioperative and early oncologic results from the MUSIC statewide collabor13
2021 Joseph A. Smith, Jr. Mentorship lecture: Discovery13
Tolerability and treatment outcome of pembrolizumab in patients with advanced urothelial carcinoma and severe renal dysfunction13
Carbonic anhydrase 10 functions as a tumor suppressor in renal cell carcinoma and its methylation is a risk factor for survival outcome13
Assessing the diagnostic performance of systematic freehand PrecisionPoint transperineal prostate biopsy: Comparison of observed outcomes to PBCG nomogram predictions13
Volume-outcome relationships for kidney cancer may be driven by disparities and patient risk13
Germline genetics in prostate cancer: Amidst a paradigm shift13
Subsequent primary urogenital cancers among childhood and adolescent cancer survivors in the United States13
COVID-19 vaccination: Prioritization of at risk groups13
Oncological outcomes of surgery for isolated retroperitoneal recurrence in renal cancer patients after radical nephrectomy13
Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy12
A new index (A/G) associated with early complications of radical cystectomy and intestinal urinary diversion12
Low co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET in urothelial carcinoma is associated with discordant expression between primary and metastatic sites12
Cover 2 - Masthead12
Biomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxel12
Prostate cancer outcomes disparities: Population survival analysis in an ethnically diverse nation12
Impact of paclitaxel, cisplatin, and gemcitabine as first-line chemotherapy in cisplatin-fit and -unfit patients with advanced/metastatic urothelial carcinoma12
High-intensity end-of-life care among Medicare beneficiaries with bladder cancer12
Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis12
A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study12
Age of menarche and primary bladder cancer risk: A meta-analysis and systematic review11
Comparing the prognostic models to predict oncologic outcomes in patients with renal cell carcinoma: is AUC close enough to clinical practice?11
Is testis sparing surgery safe in patients with incidental small testicular lesions referring to a fertility center? A retrospective analysis reporting factors correlated to malignancy and long-term o11
Feasibility and outcome of radical prostatectomy following inductive neoadjuvant therapy in patients with suspicion of rectal infiltration11
Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors11
Variability in testosterone measurement between radioimmunoassay (RIA), chemiluminescence assay (CLIA) and liquid chromatography-tandem mass spectrometry (MS) among prostate cancer patients on androge11
Reply to Khurshid R. Ghani's letter to editor regarding the article “Early experience with UGN-101 for the treatment of upper tract urothelial cancer: a multicenter evaluation of practice patterns and11
Table of Contents11
Cover 2 - Masthead11
Impact of the controlling nutritional status (CONUT) score on perioperative morbidity and oncological outcomes in patients with bladder cancer treated with radical cystectomy11
Higher prevalence of benign tumors in men with testicular tumors and history of treated cryptorchidism11
Oncologic and patient-reported outcomes after robot-assisted radical prostatectomy in men aged ≥75 years11
Does testosterone replacement therapy increase the risk of conversion to treatment in patients with prostate cancer on active surveillance?11
Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III11
SARS-CoV-2 mRNA vaccination, prostate cancer and steroids: Correspondence11
The early impact of medicaid expansion on urologic malignancies in the United States11
The effect of centralization of care on overall survival in primary urethral cancer11
Editorial Board10
Stratifying patients with intermediate-risk prostate cancer: Validation of a new model based on MRI parameters and targeted biopsy and comparison with NCCN and AUA subclassifications10
Diagnostic yield of repeat evaluation for asymptomatic microscopic hematuria after negative initial workup10
The role of enhanced recovery after surgery protocols in the development of acute kidney injury following radical cystectomy10
Comparing costs of renal preservation versus radical nephroureterectomy management among patients with non-metastatic upper tract urothelial carcinoma10
Editorial Board10
Real-world treatment patterns and outcomes of patients with unresectable or metastatic urothelial carcinoma receiving systemic therapy in Japan10
Morbidity and mortality of multivisceral resection with radical nephrectomy for locally advanced renal cell carcinoma: An analysis of the National Surgical Quality Improvement Program (NSQIP) database10
Investigation of prognostic biomarkers in patients with urothelial carcinoma treated with platinum-based regimens10
Annual mpMRI surveillance: PI-RADS upgrading and increasing trend correlated with patients who harbor clinically significant disease10
Cover 2 - Masthead10
Prognostic significance of the Ki67 index and programmed death-ligand 1 expression after radical cystectomy in patients with muscle-invasive bladder cancer10
Overall survival benefit of androgen suppression in addition to dose-escalated external beam radiotherapy for high-risk prostate cancer: Nationwide real-world data indicates a shift in men that benefi10
Defining the index lesion for potential salvage partial or hemi-gland ablation after radiation therapy for localized prostate cancer10
The pathway of isolated seminal vesicle invasion has a different impact on biochemical recurrence after radical prostatectomy and pelvic lymphadenectomy10
Multiple primary cancers in men with sporadic or familial prostate cancer: Its clinical implications10
Defining radical cystectomy using the ICD-10 procedure coding system10
Partial nephrectomy should be classified as an inpatient procedure: Results from a statewide quality improvement collaborative10
Parenchymal obliteration by renal masses: Functional and oncologic implications10
A novel nomogram predicting lymph node invasion among patients with prostate cancer: The importance of extracapsular extension at multiparametric magnetic resonance imaging9
Impact of CoVID-19 on resident and fellow education: Current guidance and future opportunities for urologic oncology training programs9
Validation of Epstein criteria and development of a nomogram for active surveillance in a contemporary Chinese population9
Evaluation of PD-L1 (E1L3N, 22C3) expression in venous tumor thrombus is superior to its assessment in renal tumor in predicting overall survival in renal cell carcinoma9
Radical prostatectomy readmissions: Causes, risk factors, national rates, & costs9
Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer9
The emerging role of cell cycle protein p53 expression by tumor cells and M2-macrophage infiltration in urinary bladder cancer9
Cover 2 - Masthead9
Nephron-sparing surgery for renal cell carcinoma in children and young adults: A systematic review9
Table of Contents9
Change in telomere length and cardiovascular risk factors in testicular cancer survivors9
Table of Contents9
Neoadjuvant chemotherapy in bladder cancer: Clinical benefit observed in prospective trials computed with restricted mean survival times9
Table of Contents9
A population-level analysis of nonsquamous penile cancer: The importance of histology9
Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study9
Alternative Complement Pathway Signature Determines Immunosuppression and Resistance to Immunotherapy Plus Tyrosine Kinase Inhibitor Combinations in Renal Cell Carcinoma9
Methodological considerations for systematic review and meta-analysis of Xpert bladder cancer monitor9
Comparing direct medical care costs of patients with bladder cancer who received an ileal conduit vs. neobladder in the year following cystectomy9
Management of anticoagulation and antiplatelet agents in the radical cystectomy patient9
Assessing pentafecta achievement after robot-assisted radical cystectomy and its association with surgical experience: Results from a high-volume institution9
Telemedicine in urologic oncology care: Will telemedicine exacerbate disparities?9
Impact of a negative confirmatory biopsy on risk of disease progression among men on active surveillance for prostate cancer9
UPDATED EFFICACY AND SAFETY OF ORAL ERDAFITINIB IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE, HIGH-RISK NON-MUSCLE–INVASIVE BLADDER CANCER WITH FGFR3/2 ALTERATIONS IN THOR-2 COHORT 28
hTERT, hTR and TERT promoter mutations as markers for urological cancers detection: A systematic review8
Determining the diagnostic value of PSMA-PET/CT imaging in patients with persistent high prostate specific antigen levels and negative prostate biopsies8
Clinical characteristics of renal cell carcinoma in patients under the age of 408
ONCOLOGIC OUTCOMES OF INTRAVESICAL THERAPY IN THE MANAGEMENT OF NON-MUSCLE INVASIVE BLADDER CANCER WITH VARIANT HISTOLOGY8
MOLECULAR CORRELATES WITH PSMA EXPRESSION IN PRIMARY PROSTATE CANCER8
THE ROLE OF OVARIAN PRESERVATION IN MAINTAINING SEXUAL FUNCTION AFTER RADICAL CYSTECTOMY8
CLINICAL, MOLECULAR AND IMMUNOHISTOCHEMICAL PROFILES OF CLEAR CELL ADENOCARCINOMA OF THE URINARY TRACT8
THE PROGNOSTIC SIGNIFICANCE AND GENETIC PROFILE OF PROSTATE CANCER WITH EXPANSILE CRIBRIFORM GLEASON PATTERN 48
DECIPHER® GENOMIC CLASSIFIER SCORE ON INITIAL BIOPSY IS ASSOCIATED WITH PROGRESSION FORM ACTIVE SURVEILLANCE TO TREATMENT IN PROSTATE CANCER8
APPLICATION OF THE STRATCANS CRITERIA TO THE MUSIC AS COHORT: A STEP TOWARDS RISK STRATIFIED ACTIVE SURVEILLANCE8
MARKER LESION STUDY OF ORAL ERDAFITINIB IN PATIENTS WITH INTERMEDIATE-RISK NON-MUSCLE–INVASIVE BLADDER CANCER WITH FGFR3/2 ALTERATIONS IN THOR-2: UPDATED COHORT 3 RESULTS8
INTER-RATER RELIABILITY AND DIAGNOSTIC ACCURACY OF PI-RADS SCORING BETWEEN ACADEMIC AND COMMUNITY CARE NETWORKS: HOW WIDE IS THE GAP8
NOVEL COMBINATION THERAPY USING INTERFERON GENE THERAPY AND GEMCITABINE IN MURINE BLADDER CANCER CELL LINES8
Race, ethnicity, and gender reporting in North American clinical trials for BCG-unresponsive non-muscle invasive bladder cancer8
Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis8
PREOPERATIVE RADICAL CYSTECTOMY ERAS SCREENING AND EDUCATION – PATIENT REPORTED OUTCOMES8
EXAMINING SURVIVAL OUTCOMES AND MOLECULAR DRIVERS OF TESTIS CANCER IN HISPANIC MEN8
DISPARITIES IN UTILIZATION OF GENETIC EVALUATION IN PATIENTS WITH KIDNEY CANCER WHO MEET GUIDELINES FOR GENETIC REFERRAL8
THE RELATIONSHIP BETWEEN SMOKING STATUS AND POOR MENTAL HEALTH IN BLADDER CANCER PATIENTS AND SURVIVORS8
LEGEND, A PHASE 1/2 STUDY OF DETALIMOGENE VORAPLASMID (EG-70) INTRAVESICAL MONOTHERAPY DEMONSTRATED CLINICAL RESPONSES IN BCG-UNRESPONSIVE NMIBC PATIENTS WITH CIS8
DECOMPRESSION OR NOT: THE ONGOING CHALLENGE OF MALIGNANT HYDRONEPHROSIS8
UNRAVELING THE WEB OF FRAILTY: A NOVEL APPROACH TO FRAILTY USING A COMPREHENSIVE GERIATRIC ASSESSMENT-DERIVED SPIDER PLOT8
ULTRASOUND ECHOGENICITY CAN RISK STRATIFY LESIONS ON MP-MRI FOR CLINICALLY SIGNIFICANT PROSTATE CANCER8
COMUTATIONAL PATTERNS IN FGFR3-ALTERED NON-MUSCLE INVASIVE BLADDER CANCER INFLUENCE RECURRENCE AND PROGRESSION8
The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancer8
A 25-year perspective on evaluation and understanding of biomarkers in urologic cancers8
Poor clinical outcomes and immunoevasive contexture in SIRPα+ tumor-associated macrophages enriched muscle-invasive bladder cancer patients8
Should grade group 1 prostate cancer be reclassified as “non-cancer”? A pathology community perspective8
COMPARISON OF PARTIAL GLAND CRYOABLATION AND ROBOTIC RADICAL PROSTATECTOMY: A PROPENSITY-SCORE MATCHED ANALYSIS8
“Published abstracts from the 24th Annual Meeting of the Society of Urologic Oncology”8
PREVALENCE OF OCCULT UROLOGIC MALIGNANCIES IN PATIENTS UNDERGOING SCREENING FOR LUNG CANCER8
IS PATHOLOGICAL UPSTAGING TO T3A RENAL CELL CARCINOMA ASSOCIATED WITH A SIMILAR PROGNOSIS TO NON-UPSTAGED PATHOLOGIC T3A DISEASE? A MULTICENTER ANALYSIS8
INCIDENTAL CARCINOMA AFTER SINGLE-PORT TRANSVESICAL ROBOT-ASSISTED SIMPLE PROSTATECTOMY8
C-REACTIVE PROTEIN KINETICS ARE ASSOCIATED WITH PROGRESSION AND SURVIVAL IN SURGICALLY TREATED RENAL CELL CARCINOMA PATIENTS8
CHARACTERIZATION OF NAV1.7 EXPRESSION IN PROSTATIC NERVES FOLLOWING RADICAL PROSTATECTOMY8
MAYO ADHESIVE PROBABILITY SCORE IS ASSOCIATED WITH WORSE OVERALL SURVIVAL IN PATIENTS UNDERGOING SURGERY FOR CLINICAL STAGE T1 RENAL CELL CARCINOMA7
GROWTH KINETICS OF VENOUS TUMOR THROMBUS IN PATIENTS WITH RENAL CELL CARCINOMA7
PSMA PET/CT-DETECTED MESORECTAL NODAL METASTASIS IN BIOCHEMICALLY RECURRENT PROSTATE CANCER PATIENTS7
SQUAMOUS CELL CARCINOMA OF THE RENAL PELVIS: TREATMENT IMPACT AND SURVIVAL OUTCOMES IN THE NATIONAL CANCER DATABASE7
Optimizing MRI-targeted prostate biopsy: the diagnostic benefit of additional targeted biopsy cores7
Management of penile cancer patients during the COVID-19 pandemic: An eUROGEN accelerated Delphi consensus study7
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma7
Carcinogenic biomarkers of exposure in the urine of heated tobacco product users associated with bladder cancer: A systematic review7
Integrated care among patients with kidney or urinary bladder cancer: An NCI patterns-of-care analysis7
Is ipsilateral systematic biopsy combined with targeted biopsy the optimal substitute for bilateral systematic biopsy combined with targeted biopsy: A systematic review and meta-analysis7
Interaction of MRI and active surveillance in prostate cancer: Time to re-evaluate the active surveillance inclusion criteria7
A NOVEL ORTHOTOPIC MURINE MODEL OF NEUROENDOCRINE BLADDER CANCER: INSIGHTS INTO THE MOLECULAR DRIVERS OF SMALL CELL BLADDER CANCER (SCBC)7
Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer7
GERMLINE VARIANTS LINKED TO OVARIAN AND BLADDER CANCER IN FEMALES: IS OVARY SPARING RADICAL CYSTECTOMY AN OPTION?7
ALTERATIONS IN THE GUT MICROBIOME ARE ASSOCIATED WITH THE DEVELOPMENT OF POSTOPERATIVE ILEUS AND INFECTIONS IN PATIENTS UNDERGOING CYSTECTOMY AND URINARY DIVERSION7
PROFILING THE TUMOR IMMUNE MICROENVIRONMENT OF PAPILLARY RENAL CELL CARCINOMA7
Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors7
NON-MUSCLE INVASIVE RECURRENCE AND MANAGEMENT DURING SURVEILLANCE IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ACHIEVE CLINICAL COMPLETE RESPONSE TO NEOADJUVANT CHEMOTHERAPY7
Histological variants of non–muscle invasive bladder cancer: Survival outcomes of radical cystectomy vs. bladder preservation therapy7
National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy7
Prognostic nutritional index and prognosis in renal cell carcinoma: A systematic review and meta-analysis7
Editorial Board7
The impact of pretreatment PSA on risk stratification in men with Gleason 6 prostate cancer: Implications for active surveillance7
Predictive factors associated with differential pathologic response to neoadjuvant chemohormonal therapy in high-risk localized prostate cancer7
Engaging disparities in prostate cancer: Piloting an interactive, virtual workshop to educate providers on shared decision-making for underserved populations7
IMMUNOTHERAPY UTILIZATION PATTERNS IN METASTATIC BLADDER CANCER: ASSESSING INSURANCE STATUS AS A MODIFIABLE FACTOR ASSOCIATED WITH FAILURE TO RECEIVE NOVEL THERAPIES7
REAL-WORLD ANALYSES OF MACE AND MORTALITY RISK IN PATIENTS WITH PROSTATE CANCER AFTER INITIATION OF LHRH AGONISTS VS. GNRH ANTAGONIST7
SWOG S1931 (PROBE): PHASE III RANDOMIZED TRIAL OF IMMUNE CHECKPOINT INHIBITOR (ICI) COMBINATION REGIMEN WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY (CN) IN ADVANCED RENAL CANCER [NCT04510597]7
COMPARISON OF APIXABAN VERSUS ENOXAPARIN FOR EXTENDED PROPHYLAXIS AFTER RADICAL CYSTECTOMY (CARE)7
Bladder cancer risk stratification using a urinary mRNA biomarker panel – A path towards cystoscopy triaging7
Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer7
Oncologic outcomes of intravesical therapy in the management of nonmuscle invasive bladder cancer with variant histology7
Multicenter transperineal MRI-TRUS fusion guided outpatient clinic prostate biopsies under local anesthesia7
The assessment of bladder cancer resectability with bimanual palpation: A prospective study in laparoscopy and open cystectomy patients7
Clinicopathological significance and prognostic value of cancer-associated fibroblasts in prostate cancer patients7
The impact of life expectancy on cost-effectiveness of treatment options for clinically localized prostate cancer7
The impact of local staging of prostate cancer determined on MRI or DRE at time of radical prostatectomy on progression-free survival: A Will Rogers phenomenon6
The prognostic significance of circulating tumor DNA in patients with positive lymph node disease after robotic-assisted radical cystectomy: A contemporary analysis6
Controversies in prostate cancer screening6
A 25-year review of advances in testicular cancer: Perspectives on evaluation, treatment, and future directions/challenges6
Inguinal lymph node dissection in the era of minimally invasive surgical technology6
Differences in the treatment patterns of small renal masses: A disaggregated analyses by race/ethnicity6
Adjuvant immunotherapy in high-risk muscle invasive urothelial carcinoma: A systematic review and meta-analysis of randomized clinical trials6
Utilization and outcomes of metastasectomy for patients with metastatic urothelial cancer: An analysis of the national cancer database6
Editorial Board6
Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors6
Reducing the demand for magnetic resonance imaging scans and prostate biopsies during the early detection of clinically significant prostate cancer: Applying the Barcelona risk-stratified pathway in C6
The effect of tumor grade heterogeneity on recurrence in non-muscle invasive bladder cancer6
Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA)6
Comparison of the prognosis of primary vs. progressive muscle invasive bladder cancer after radical cystectomy: Results from a large multicenter study6
The natural history of muscle-invasive bladder cancer in geriatric patients undergoing transurethral resection only: Outcome and cost6
Cover 2 - Masthead6
Impact of heavy metals, oxidative stress, expression of VHL, and antioxidant genes in the pathogenesis of renal cell carcinoma6
Exploring the opportunities and challenges of implementing artificial intelligence in healthcare: A systematic literature review6
The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer6
The increasing use of renal tumor biopsy amongst Canadian urologists: When is biopsy most utilized?6
Management of urologic cancers during the pandemic and potential impact of treatment deferrals on outcomes6
Is YouTube a good resource for patients to better understand kidney cancer?6
Systemic dissemination of tumor cells during transurethral resection in patients with bladder tumor and its clinical relevance: A follow up study6
Estimates of the lead time in screening for bladder cancer6
Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study6
Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition6
Locoregional recurrence after cystectomy in muscle invasive bladder cancer: Implications for adjuvant radiotherapy6
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-026
Anterior and apical samplings during transperineal image-guided prostate biopsy6
Causal relationship between bladder cancer and gut microbiota contributes to the gut-bladder axis: A two-sample Mendelian randomization study6
Trends in the use of immediate postoperative intravesical chemotherapy following transurethral resection of bladder tumors6
Table of Contents6
The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients6
Functional outcomes after prostate cancer treatment: A comparison between single and multiple modalities6
Randomized trials of PSA screening6
Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review6
Prognostic significance of pT3a staging subclassifications in renal cell carcinoma: Not all pT3a are equal6
How does a prebiopsy mri approach for prostate cancer diagnosis affect prostatectomy upgrade rates?6
Applications of artificial intelligence in prostate cancer histopathology6
Seminar: Revisiting the value of PSA-based prostate cancer screening Essay No 5: Should men undergo MRI before prostate biopsy? (Pro)6
Early experience with sequential intravesical gemcitabine and docetaxel for micropapillary variant non-muscle invasive bladder cancer6
Harnessing choice architecture in urologic practice: Implementation of an opioid-sparing protocol grounded in cognitive behavioral theory6
The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis6
The impact of metabolic syndrome on short term radical cystectomy complications6
0.096107959747314